A new type of antidepressant, developed by researchers at the University of Carville in partnership with colleagues around the world, has been approved for use in Lauchenoiria following several rounds of successful clinical trials. The new drug will be available on prescription for adult patients diagnosed with persistent depression lasting over one year, Obsessive Compulsive Disorder (OCD), or Post-Traumatic Stress Disorder (PTSD).
The new antidepressant works more quickly than previous drugs of this class, and with fewer side effects on average. The development, and especially domestic production, of the new drug will likely help resolve many supply issues Lauchenoiria has faced in PTSD treatment since the end of the Second Lauchenoirian Civil War in 2018, where a shortage of PTSD medications was reported.
Professor Roberto Vilaseca, an expert in biomedical science at the University of Carville, told the Lauchenoirian Guardian that this would “revolutionise the treatment of several mental health disorders across the world, providing relief to many patients suffering from these conditions – especially those whose conditions have proven resistant to other treatment.”
“While therapies such as Cognitive Behavioural Therapy (CBT) and talking therapies play a large part in the treatment of these conditions,” he went on to say, “often it can be difficult to begin and engage in therapy without pharmaceutical treatment to begin with; and medication provides a necessary counterpart to therapy in treating many mental illnesses for many patients.”
Trials are also ongoing to see if the drug can also be offered to adolescents with OCD, with promising early results.
